Kistler-Tiffany Companies’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Kistler-Tiffany Companies’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	–	–	851
2022 Q3	$0	Hold	300	–	–	﹤0.01%	835
2022 Q2	$0	Hold	300	–	–	﹤0.01%	806
2022 Q1	$0	Hold	300	–	–	﹤0.01%	784
2021 Q4	$1K	Hold	300	–	–	﹤0.01%	723
2021 Q3	$1K	Hold	300	–	–	﹤0.01%	730
2021 Q2	$1K	Hold	300	–	–	﹤0.01%	723
2021 Q1	$1K	Hold	300	–	–	﹤0.01%	664
2020 Q4	$1K	Hold	300	–	–	﹤0.01%	642
2020 Q3	$1K	Hold	300	–	–	﹤0.01%	627
2020 Q2	$1K	Hold	300	–	–	﹤0.01%	583
2020 Q1	$2K	Hold	300	–	–	﹤0.01%	545
2019 Q4	$2K	Hold	300	–	–	﹤0.01%	551
2019 Q3	$1K	Hold	300	–	–	﹤0.01%	581
2019 Q2	$4K	Buy	+300	New	+$3.68K	﹤0.01%	526

Other funds holding PHAS

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HLA

Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return

IIA

IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Kistler-Tiffany Companies's PHAS Position: Q4 2022 in Review

Kistler-Tiffany Companies sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 300 shares.

Kistler-Tiffany Companies first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $4K in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

Kistler-Tiffany Companies reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Kistler-Tiffany Companies sold 300 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022.
Kistler-Tiffany Companies first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
Kistler-Tiffany Companies's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $4K in Q2 2019.
5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Kistler-Tiffany Companies's 13F filing for Q4 2022, filed 30 Jan 2023.